These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15783085)

  • 1. MHC class I down regulation, tumour escape from immune surveillance and design of therapeutic strategies.
    Bubeník J
    Folia Biol (Praha); 2005; 51(1):1-2. PubMed ID: 15783085
    [No Abstract]   [Full Text] [Related]  

  • 2. MHC class I down-regulation: tumour escape from immune surveillance? (review).
    Bubeník J
    Int J Oncol; 2004 Aug; 25(2):487-91. PubMed ID: 15254748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MHC class I antigens and immune surveillance in transformed cells.
    Aptsiauri N; Cabrera T; Garcia-Lora A; Lopez-Nevot MA; Ruiz-Cabello F; Garrido F
    Int Rev Cytol; 2007; 256():139-89. PubMed ID: 17241907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T lymphocyte-derived TNF and IFN-γ repress HFE expression in cancer cells.
    Reuben A; Godin-Ethier J; Santos MM; Lapointe R
    Mol Immunol; 2015 Jun; 65(2):259-66. PubMed ID: 25700349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer.
    Burr ML; Sparbier CE; Chan KL; Chan YC; Kersbergen A; Lam EYN; Azidis-Yates E; Vassiliadis D; Bell CC; Gilan O; Jackson S; Tan L; Wong SQ; Hollizeck S; Michalak EM; Siddle HV; McCabe MT; Prinjha RK; Guerra GR; Solomon BJ; Sandhu S; Dawson SJ; Beavis PA; Tothill RW; Cullinane C; Lehner PJ; Sutherland KD; Dawson MA
    Cancer Cell; 2019 Oct; 36(4):385-401.e8. PubMed ID: 31564637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression.
    Kriegsman BA; Vangala P; Chen BJ; Meraner P; Brass AL; Garber M; Rock KL
    J Immunol; 2019 Oct; 203(7):1999-2010. PubMed ID: 31471524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects.
    Oliveira CC; van Veelen PA; Querido B; de Ru A; Sluijter M; Laban S; Drijfhout JW; van der Burg SH; Offringa R; van Hall T
    J Exp Med; 2010 Jan; 207(1):207-21. PubMed ID: 20038604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It.
    Shklovskaya E; Rizos H
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Towards a holistic vision of cancer].
    Solary É; Laplane L
    Med Sci (Paris); 2016 Apr; 32(4):315-6. PubMed ID: 27137681
    [No Abstract]   [Full Text] [Related]  

  • 10. MHC class I antigens, immune surveillance, and tumor immune escape.
    Garcia-Lora A; Algarra I; Garrido F
    J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replicative senescence of CD8 T cells: potential effects on cancer immune surveillance and immunotherapy.
    Effros RB
    Cancer Immunol Immunother; 2004 Oct; 53(10):925-33. PubMed ID: 15067431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How tumors escape immune destruction and what we can do about it.
    Gilboa E
    Cancer Immunol Immunother; 1999 Oct; 48(7):382-5. PubMed ID: 10501851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xenopus, a unique comparative model to explore the role of certain heat shock proteins and non-classical MHC class Ib gene products in immune surveillance.
    Robert J; Goyos A; Nedelkovska H
    Immunol Res; 2009 Dec; 45(2-3):114-22. PubMed ID: 19189057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Membrane-bound versus soluble major histocompatibility complex Class I-related chain A and major histocompatibility complex Class I-related chain B differential expression: Mechanisms of tumor eradication versus evasion and current drug development strategies.
    Suresh PK
    J Cancer Res Ther; 2016; 12(4):1224-1233. PubMed ID: 28169232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.
    van Hall T; Wolpert EZ; van Veelen P; Laban S; van der Veer M; Roseboom M; Bres S; Grufman P; de Ru A; Meiring H; de Jong A; Franken K; Teixeira A; Valentijn R; Drijfhout JW; Koning F; Camps M; Ossendorp F; Kärre K; Ljunggren HG; Melief CJ; Offringa R
    Nat Med; 2006 Apr; 12(4):417-24. PubMed ID: 16550190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From tumor cell metabolism to tumor immune escape.
    Villalba M; Rathore MG; Lopez-Royuela N; Krzywinska E; Garaude J; Allende-Vega N
    Int J Biochem Cell Biol; 2013 Jan; 45(1):106-13. PubMed ID: 22568930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Playing hide and seek: Tumor cells in control of MHC class I antigen presentation.
    Jongsma MLM; Neefjes J; Spaapen RM
    Mol Immunol; 2021 Aug; 136():36-44. PubMed ID: 34082257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunoediting from immune surveillance to immune escape.
    Kim R; Emi M; Tanabe K
    Immunology; 2007 May; 121(1):1-14. PubMed ID: 17386080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escape from immune- and nonimmune-mediated tumor surveillance.
    Malmberg KJ; Ljunggren HG
    Semin Cancer Biol; 2006 Feb; 16(1):16-31. PubMed ID: 16140546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
    Humphreys RE; Hillman GG; von Hofe E; Xu M
    Cell Mol Immunol; 2004 Jun; 1(3):180-5. PubMed ID: 16219165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.